Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies. With a robust pipeline of promising drug candidates focused on precision oncology, the company is uniquely positioned to address critical unmet needs in cancer care. Strategic collaborations with top academic institutions bolster its research and development efforts, enhancing its ability to deliver transformative therapeutic solutions. Tango Therapeutics aims to significantly improve patient outcomes and redefine treatment paradigms in oncology, making it a compelling investment opportunity in the biopharmaceutical landscape.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$22.52
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 4, 2026 | $-0.31 | $-0.37 | Miss -19.4% | $-0.37 | $0 | $0 | — | 1D Pre+0.1% | On-Day+7.9% | 1D Post-1.9% |
Q ended Mar 31, 2026 Reported May 13, 2026 | $-0.29 | $-0.32 | Miss -10.3% | $-0.32 | $578.1K | $0 | -100.0% | 1D Pre+0.1% | On-Day+8.6% | 1D Post-2.5% |
Q ended Dec 31, 2025 Reported Mar 5, 2026 | $-0.31 | $-0.29 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $500.4K |
| $0 |
| -100.0% |
| 1D Pre+7.4% |
| On-Day+36.3% |
| 1D Post+0.7% |
Q ended Sep 30, 2025 Reported Nov 4, 2025 | $-0.07 | $-0.14 | Miss -100.0% | — | $41.2M | $53.8M | +30.6% | 1D Pre-1.2% | On-Day0.0% | 1D Post-6.2% |